Table 2.
Clinical results
| Masked ID | Initial visual acuity | 6-month visual acuity | 6-month IOP | MTX dosage | Number of MTX injections | PFCL duration (weeks) | Redetachment (Y/N) | Duration of follow-up (months) |
| MTX 1 | CF 2 feet | HM | 4 | 200 µg/0.05 mL | 12 | 5 | N | 27 |
| MTX 2 | HM | 20/200 | 12 | 200 µg/0.05 mL | 5 | 5 | N | 22 |
| MTX 3 | 20/400 | 20/400 | 14 | 100 µg/0.05 mL | 5 | 4 | N | 15 |
| MTX 4 | 20/200 | 20/60 | 10 | 100 µg/0.05 mL | 5 | 5 | N | 12 |
| MTX 5 | HM | 20/100 | 10 | 100 µg/0.05 mL | 5 | 4 | N | 11 |
IOP, intraocular pressure; MTX, methotrexate; PFCL, perfluorocarbon liquid.